Latest News

Here’s How LSD Can Treat Depression

Read More

Optimi Health to Enter Asian Market with PsiloThai Collaboration on Psilocybin Research

Vancouver, British Columbia–(Newsfile Corp. – July 23, 2024) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, is pleased to announce a strategic supply partnership and Letter of Intent with PsiloThai, a leading patient advocacy group…

Psilocybin’s Impact on Brain Activity

Psilocybin, the primary psychoactive compound found in hallucinogenic mushrooms, has long intrigued scientists and enthusiasts alike for its profound effects on perception and consciousness. Recent research conducted by the Washington University School of Medicine in St. Louis sheds new light on how this compound impacts the brain, offering promising insights into its potential therapeutic uses….

Awakn life sciences

Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio

Toronto, Ontario–(Newsfile Corp. – July 22, 2024) – Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder (“AUD”), is pleased to provide details of the status of the intellectual…

Reunion Neuroscience

Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression

Reunion Neuroscience Inc. announced that the first patient has been dosed in the RECONNECT Phase 2 clinical trial of RE104 for the treatment of postpartum depression (PPD). RE104 was designed to be a safe, fast-acting, single-dose therapy to benefit patients suffering from underserved mental health disorders, including PPD. The RECONNECT Phase 2 clinical trial (NCT06342310)…